Peptides DB
Research-centric peptide and protocol reference hub
Study 24 of 24Teriparatide (PTH 1-34) literaturebiorxiv-preprint · Case report2023

Phenotypic-Genotypic Discordance in Renal Tubular Acidosis with Hypokalemic Rhabdomyolysis and a TRAPPC2 Variant: A Case Report

This case underscores the diagnostic challenges of renal tubular acidosis and highlights the importance of considering metabolic and skeletal disorders in similar presentations.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the teriparatide (pth 1-34) corpus
1
Preclinical
18
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This case report discusses a man in his early twenties with renal tubular acidosis (RTA) and hypokalemic rhabdomyolysis. The patient was treated with potassium citrate, sodium bicarbonate, calcium, cholecalciferol, and teriparatide, resulting in improved symptoms and bone mineral density after one year. The case highlights the complexities of diagnosing discordant renal tubular phenotypes and associated genetic findings.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Serum potassium was 1.7 mmol/L during an acute episode.n=12023

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p>Background Renal tubular acidosis (RTA) encompasses disorders of renal acid–base regulation that may cause hypokalemia, metabolic bone disease, and growth retardation. Distal RTA (dRTA) is characterized by hyperchloremic, normal-anion-gap metabolic acidosis with urine pH > 5.5. Distinguishing proximal from distal RTA is challenging when clinical, biochemical, and genetic findings are discordant. Hypokalemia-induced rhabdomyolysis is uncommon, and the coexistence of RTA with spondyloepiphyseal dysplasia tarda (SEDT) remains poorly characterized. Case presentation A normotensive man in his early twenties presented with an eight-year history of recurrent hypokalemic flaccid quadriparesis, myalgia, polyuria, short stature, severe back pain, and impaired mobility. During an acute episode, serum potassium was 1.7 mmol/L and creatine phosphokinase (CPK) was 17,384 U/L, suggesting hypokalemia-induced rhabdomyolysis. Subsequent investigations demonstrated hyperchloremic normal-anion-gap metabolic acidosis, urine pH > 5.5, a positive urinary anion gap, hypercalciuria, hypophosphatemia, hypouricemia, and bilateral medullary nephrocalcinosis, supporting a distal RTA phenotype. Imaging revealed osteomalacia, pseudofractures, kyphosis, and bilateral sacroiliitis; dual-energy X-ray absorptiometry (DEXA) scan showed severe osteoporosis. Back pain and sacroiliitis initially suggested seronegative spondyloarthropathy (SSpA), but normal inflammatory markers, negative HLA-B27, and lack of response to immunomodulatory therapy prompted diagnostic reconsideration. Whole-exome sequencing identified heterozygous GATM c.181C > G (p.Pro61Ala) and hemizygous TRAPPC2 c.176T > C (p.Met59Thr) variants of uncertain significance. The GATM variant is associated with Fanconi renotubular syndrome type 1, despite the predominantly distal RTA phenotype. Maternal Sanger sequencing confirmed heterozygosity for the TRAPPC2 variant. Disproportionate short stature and skeletal abnormalities raised suspicion of coexisting X-linked SEDT. Treatment with potassium citrate, sodium bicarbonate, calcium, cholecalciferol, and teriparatide improved symptoms and bone mineral density at one year, although mild metabolic acidosis persisted. Conclusions This case highlights the diagnostic complexity of discordant renal tubular phenotypes and genetic findings. Hypokalemic rhabdomyolysis and metabolic bone disease may provide important diagnostic clues. Sacroiliitis may mimic inflammatory spondyloarthritis, emphasizing the need to consider metabolic and skeletal disorders. Further segregation and functional studies are needed to clarify the identified variants and investigate a possible association between RTA and SEDT.</p>

Background

This paper addresses the complexities of diagnosing renal tubular acidosis (RTA) when clinical, biochemical, and genetic findings are discordant. Prior knowledge indicates that RTA can lead to various complications, including hypokalemia and metabolic bone disease. Understanding the interplay between genetic variants and phenotypic presentations is critical for accurate diagnosis and management.

Methods

This is a case report detailing the clinical presentation and genetic findings of a single patient. The patient underwent whole-exome sequencing to identify genetic variants. Treatment included potassium citrate, sodium bicarbonate, calcium, cholecalciferol, and teriparatide over a one-year period.

Results

The primary endpoint of the case was the improvement in symptoms and bone mineral density after treatment, although specific numeric results were not provided. The patient exhibited severe osteoporosis and hypokalemic rhabdomyolysis, with significant laboratory findings supporting a diagnosis of distal RTA.

Interpretation

The findings highlight the diagnostic challenges in cases of discordant renal tubular phenotypes and genetic variants. While the treatment led to symptom improvement, the clinical significance of the observed changes remains unclear due to the lack of detailed numeric outcomes. The limitations of a single-case report and the need for further studies to validate the findings are important considerations for clinical practice.

Key findings

  • Serum potassium was 1.7 mmol/L during an acute episode.
  • Creatine phosphokinase (CPK) was 17,384 U/L, indicating hypokalemia-induced rhabdomyolysis.
  • DEXA scan showed severe osteoporosis.
  • Treatment improved symptoms and bone mineral density at one year.

Limitations

  • Single-case report limits generalizability.
  • No detailed numeric outcomes reported for treatment effects.
  • Further studies needed to clarify genetic variants.

Elsewhere in the Teriparatide (PTH 1-34) corpus

DPerioperative Anabolic Osteoporosis Pharmacotherapy Is Associated With Lower Rates of Proximal Junctional Kyphosis After Adult Spinal Deformity Surgery: A Systematic Review and Meta-Analysis.Spine · 2026 · PJK odds reduced with anabolic pharmacotherapy, pooled OR 0.51, 95% CI 0.30 to 0.86, P=0.012, I2=0%, k=5.reviewCCombined Teriparatide and Exercise Effects on Diabetic Skeletal Muscle Ultrastructure.In vivo (Athens, Greece) · 2026 · Not reported in abstract.AnimalDParathyroid Hormone for Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis.Oral diseases · 2026 · Odds ratio 5.81.reviewBReal-World Effectiveness of Osteoporosis Treatments on Bone Strength and the Impact of Sequential Anabolic Therapybiorxiv-preprint · 2026 · 39.5% increase in vertebral strength with Romo at 12 months, n=57, 95% CI [34.2, 44.7]HumanABioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial.The Lancet. Digital health · 2026 · n=242 · Global relative patency of 1·17 (95% CI 1·04-1·31, p=0·0090).HumanCAscorbic acid mitigates oxidative structural degradation in bovine spermatozoa: a label-free quantitative phase microscopy study.Veterinary and animal science · 2026 · Not reported in abstract.Animal